Fintel reports that on August 21, 2024, Chardan Capital initiated coverage of Clearside Biomedical (NasdaqGM:CLSD) with a Buy recommendation.
Analyst Price Forecast Suggests 455.45% Upside
As of August 6, 2024, the average one-year price target for Clearside Biomedical is $5.61/share. The forecasts range from a low of $4.04 to a high of $8.40. The average price target represents an increase of 455.45% from its latest reported closing price of $1.01 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Clearside Biomedical is 7MM, a decrease of 11.27%. The projected annual non-GAAP EPS is -0.65.
What is the Fund Sentiment?
There are 65 funds or institutions reporting positions in Clearside Biomedical. This is an decrease of 3 owner(s) or 4.41% in the last quarter. Average portfolio weight of all funds dedicated to CLSD is 0.04%, an increase of 27.91%. Total shares owned by institutions decreased in the last three months by 10.19% to 14,536K shares. 
The put/call ratio of CLSD is 0.00, indicating a bullish outlook.
What are Other Shareholders Doing?
Rosalind Advisors holds 2,593K shares representing 3.47% ownership of the company. No change in the last quarter.
Armistice Capital holds 2,136K shares representing 2.86% ownership of the company. In its prior filing, the firm reported owning 3,956K shares , representing a decrease of 85.21%. The firm decreased its portfolio allocation in CLSD by 56.47% over the last quarter.
Carmignac Gestion holds 2,133K shares representing 2.85% ownership of the company. No change in the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,654K shares representing 2.21% ownership of the company. In its prior filing, the firm reported owning 1,384K shares , representing an increase of 16.35%. The firm increased its portfolio allocation in CLSD by 42.53% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 730K shares representing 0.98% ownership of the company. In its prior filing, the firm reported owning 707K shares , representing an increase of 3.11%. The firm increased its portfolio allocation in CLSD by 26.89% over the last quarter.
Clearside Biomedical Background Information
(This description is provided by the company.)
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company's SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
